Serzyl 25 mikrograma/125 mikrograma po potisku, stlačeni inhalat, suspenzija
| Name | Serzyl 25 mikrograma/125 mikrograma po potisku, stlačeni inhalat, suspenzija |
|---|---|
| Former Name | Sirdupla 25 mikrograma/125 mikrograma po potisku, stlačeni inhalat, suspenzija |
| Marketing Authorisation Number | HR-H-254713416 |
| Active Substance | salmeterolksinafoat flutikazonpropionat |
| Composition | jedna odmjerna doza (potiskom preko ventila) sadrži: 25 mikrograma salmeterola (u obliku salmeterolksinafoata) i 125 mikrograma flutikazonpropionata. To odgovara isporučenoj dozi (preko nastavka za usta) od 21 mikrograma salmeterola i 110 mikrograma flutikazonpropionata |
| Pharmaceutical Form | stlačeni inhalat, suspenzija |
| Manufacturer | McDermott Laboratories Limited, t/a Gerard Laboratories, Dublin 13, Irska McDermott Laboratories Limited, t/a Mylan Dublin Respiratory, Dublin 13, Irska |
| Marketing Authorisation Holder | Viatris Hrvatska d.o.o., Koranska 2, Zagreb, Hrvatska |
| Marketing Authorisation Date | 16.10.2020 |
| MA Period of Validity | unlimited |
| Classification Number | UP/I-530-09/19-02/154 |
| Registration Number | 381-12-01/38-20-04 |
| Prescription | Medicinal product subject to medical prescription |
| Type of prescription | Medicinal product on medical prescription for renewable delivery |
| Distribution | Supply through pharmacies (community) |
| Advertising to general public | not allowed |
| ATC Code | R03AK06 |
| Marketing status | Marketed |
| Shortage status | No shortage |
| SmPC | download |
| PL | download |
| Public Assessment Report | download |
